Skip to main content
Top
Published in: Diabetologia 6/2017

01-06-2017 | Article

Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans

Authors: Mahesha H. Gangadhariah, Blake W. Dieckmann, Louise Lantier, Li Kang, David H. Wasserman, Manuel Chiusa, Charles F. Caskey, Jaime Dickerson, Pengcheng Luo, Jorge L. Gamboa, Jorge H. Capdevila, John D. Imig, Chang Yu, Ambra Pozzi, James M. Luther

Published in: Diabetologia | Issue 6/2017

Login to get access

Abstract

Aims/hypothesis

Insulin resistance is frequently associated with hypertension and type 2 diabetes. The cytochrome P450 (CYP) arachidonic acid epoxygenases (CYP2C, CYP2J) and their epoxyeicosatrienoic acid (EET) products lower blood pressure and may also improve glucose homeostasis. However, the direct contribution of endogenous EET production on insulin sensitivity has not been previously investigated. In this study, we tested the hypothesis that endogenous CYP2C-derived EETs alter insulin sensitivity by analysing mice lacking CYP2C44, a major EET producing enzyme, and by testing the association of plasma EETs with insulin sensitivity in humans.

Methods

We assessed insulin sensitivity in wild-type (WT) and Cyp2c44 −/− mice using hyperinsulinaemic–euglycaemic clamps and isolated skeletal muscle. Insulin secretory function was assessed using hyperglycaemic clamps and isolated islets. Vascular function was tested in isolated perfused mesenteric vessels. Insulin sensitivity and secretion were assessed in humans using frequently sampled intravenous glucose tolerance tests and plasma EETs were measured by mass spectrometry.

Results

Cyp2c44 −/− mice showed decreased glucose tolerance (639 ± 39.5 vs 808 ± 37.7 mmol/l × min for glucose tolerance tests, p = 0.004) and insulin sensitivity compared with WT controls (hyperinsulinaemic clamp glucose infusion rate average during terminal 30 min 0.22 ± 0.02 vs 0.33 ± 0.01 mmol kg−1 min−1 in WT and Cyp2c44 −/− mice respectively, p = 0.003). Although glucose uptake was diminished in Cyp2c44 −/− mice in vivo (gastrocnemius Rg 16.4 ± 2.0 vs 6.2 ± 1.7 μmol 100 g−1 min−1, p < 0.01) insulin-stimulated glucose uptake was unchanged ex vivo in isolated skeletal muscle. Capillary density was similar but vascular KATP-induced relaxation was impaired in isolated Cyp2c44 −/− vessels (maximal response 39.3 ± 6.5% of control, p < 0.001), suggesting that impaired vascular reactivity produces impaired insulin sensitivity in vivo. Similarly, plasma EETs positively correlated with insulin sensitivity in human participants.

Conclusions/interpretation

CYP2C-derived EETs contribute to insulin sensitivity in mice and in humans. Interventions to increase circulating EETs in humans could provide a novel approach to improve insulin sensitivity and treat hypertension.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846CrossRefPubMed Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846CrossRefPubMed
2.
go back to reference Reaven G (2012) Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol 32:1754–1759CrossRefPubMed Reaven G (2012) Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol 32:1754–1759CrossRefPubMed
4.
go back to reference Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M (2000) Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 27:855–865CrossRefPubMed Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M (2000) Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 27:855–865CrossRefPubMed
5.
go back to reference Spector AA, Fang X, Snyder GD, Weintraub NL (2004) Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43:55–90CrossRefPubMed Spector AA, Fang X, Snyder GD, Weintraub NL (2004) Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43:55–90CrossRefPubMed
7.
go back to reference Capdevila J, Wang W (2013) Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr Opin Nephrol Hypertens 22:163–169CrossRefPubMedPubMedCentral Capdevila J, Wang W (2013) Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr Opin Nephrol Hypertens 22:163–169CrossRefPubMedPubMedCentral
8.
go back to reference Sun P, Antoun J, Lin DH et al (2012) Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hypertension 59:339–347CrossRefPubMed Sun P, Antoun J, Lin DH et al (2012) Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hypertension 59:339–347CrossRefPubMed
9.
go back to reference DeLozier TC, Tsao CC, Coulter SJ et al (2004) CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 310:845–854CrossRefPubMed DeLozier TC, Tsao CC, Coulter SJ et al (2004) CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 310:845–854CrossRefPubMed
10.
go back to reference Capdevila JH, Pidkovka N, Mei S et al (2014) The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem 289:4377–4386CrossRefPubMed Capdevila JH, Pidkovka N, Mei S et al (2014) The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem 289:4377–4386CrossRefPubMed
11.
go back to reference Sodhi K, Inoue K, Gotlinger KH et al (2009) Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther 331:906–916CrossRefPubMedPubMedCentral Sodhi K, Inoue K, Gotlinger KH et al (2009) Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther 331:906–916CrossRefPubMedPubMedCentral
12.
go back to reference Theken KN, Deng Y, Schuck RN et al (2012) Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab 302:E500–E509CrossRefPubMed Theken KN, Deng Y, Schuck RN et al (2012) Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab 302:E500–E509CrossRefPubMed
13.
go back to reference Luo P, Chang HH, Zhou Y et al (2010) Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 334:430–438CrossRefPubMedPubMedCentral Luo P, Chang HH, Zhou Y et al (2010) Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 334:430–438CrossRefPubMedPubMedCentral
14.
go back to reference Luria A, Bettaieb A, Xi Y et al (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A 108:9038–9043CrossRefPubMedPubMedCentral Luria A, Bettaieb A, Xi Y et al (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A 108:9038–9043CrossRefPubMedPubMedCentral
15.
go back to reference Iyer A, Kauter K, Alam MA et al (2012) Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res 2012:758614CrossRefPubMed Iyer A, Kauter K, Alam MA et al (2012) Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res 2012:758614CrossRefPubMed
17.
go back to reference Zanchi A, Maillard M, Jornayvaz FR et al (2010) Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia 53:1568–1575CrossRefPubMed Zanchi A, Maillard M, Jornayvaz FR et al (2010) Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia 53:1568–1575CrossRefPubMed
18.
go back to reference Imig JD, Zhao X, Zaharis CZ et al (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975–981CrossRefPubMedPubMedCentral Imig JD, Zhao X, Zaharis CZ et al (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975–981CrossRefPubMedPubMedCentral
19.
go back to reference Pozzi A, Popescu V, Yang S et al (2010) The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem 285:12840–12850CrossRefPubMedPubMedCentral Pozzi A, Popescu V, Yang S et al (2010) The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem 285:12840–12850CrossRefPubMedPubMedCentral
20.
go back to reference Luther JM, Luo P, Kreger MT et al (2011) Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54:2152–2163CrossRefPubMedPubMedCentral Luther JM, Luo P, Kreger MT et al (2011) Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54:2152–2163CrossRefPubMedPubMedCentral
21.
go back to reference Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG (2011) Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes 60:2515–2522CrossRefPubMedPubMedCentral Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG (2011) Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes 60:2515–2522CrossRefPubMedPubMedCentral
22.
go back to reference Williams CA, Shih MF, Taberner PV (1999) Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the β3 agonist SR 58611A. Br J Pharmacol 128:1586–1592CrossRefPubMedPubMedCentral Williams CA, Shih MF, Taberner PV (1999) Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the β3 agonist SR 58611A. Br J Pharmacol 128:1586–1592CrossRefPubMedPubMedCentral
23.
go back to reference Mizunoya W, Wakamatsu J, Tatsumi R, Ikeuchi Y (2008) Protocol for high-resolution separation of rodent myosin heavy chain isoforms in a mini-gel electrophoresis system. Anal Biochem 377:111–113CrossRefPubMed Mizunoya W, Wakamatsu J, Tatsumi R, Ikeuchi Y (2008) Protocol for high-resolution separation of rodent myosin heavy chain isoforms in a mini-gel electrophoresis system. Anal Biochem 377:111–113CrossRefPubMed
24.
go back to reference Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC t Method. Methods 25:402–408 Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC t Method. Methods 25:402–408
25.
go back to reference Gilbert K, Nian H, Yu C, Luther JM, Brown NJ (2013) Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens 31:820–829CrossRefPubMedPubMedCentral Gilbert K, Nian H, Yu C, Luther JM, Brown NJ (2013) Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens 31:820–829CrossRefPubMedPubMedCentral
26.
go back to reference Hill KD, Eckhauser AW, Marney A, Brown NJ (2009) Phosphodiesterase 5 inhibition improves β-cell function in metabolic syndrome. Diabetes Care 32:857–859CrossRefPubMedPubMedCentral Hill KD, Eckhauser AW, Marney A, Brown NJ (2009) Phosphodiesterase 5 inhibition improves β-cell function in metabolic syndrome. Diabetes Care 32:857–859CrossRefPubMedPubMedCentral
27.
go back to reference Ayers K, Byrne LM, DeMatteo A, Brown NJ (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893–898CrossRefPubMedPubMedCentral Ayers K, Byrne LM, DeMatteo A, Brown NJ (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893–898CrossRefPubMedPubMedCentral
28.
go back to reference Karara A, Wei S, Spady D, Swift L, Capdevila JH, Falck JR (1992) Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 182:1320–1325CrossRefPubMed Karara A, Wei S, Spady D, Swift L, Capdevila JH, Falck JR (1992) Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 182:1320–1325CrossRefPubMed
29.
go back to reference Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6:45–86CrossRefPubMed Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6:45–86CrossRefPubMed
30.
go back to reference Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003–1015CrossRefPubMed Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003–1015CrossRefPubMed
31.
go back to reference R Core Team (2014) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available from www.R-project.org/. Accessed 8 Mar 2017. R Core Team (2014) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available from www.​R-project.​org/. Accessed 8 Mar 2017.
33.
go back to reference Klett EL, Chen S, Edin ML et al (2013) Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion. J Biol Chem 288:21618–21629CrossRefPubMedPubMedCentral Klett EL, Chen S, Edin ML et al (2013) Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion. J Biol Chem 288:21618–21629CrossRefPubMedPubMedCentral
34.
35.
go back to reference Kang L, Ayala JE, Lee-Young RS et al (2011) Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin α2β1 in mice. Diabetes 60:416–426CrossRefPubMedPubMedCentral Kang L, Ayala JE, Lee-Young RS et al (2011) Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin α2β1 in mice. Diabetes 60:416–426CrossRefPubMedPubMedCentral
36.
go back to reference Shim CY, Kim S, Chadderdon S et al (2014) Epoxyeicosatrienoic acids mediate insulin-mediated augmentation in skeletal muscle perfusion and blood volume. Am J Physiol Endocrinol Metab 307:E1097–E1104CrossRefPubMedPubMedCentral Shim CY, Kim S, Chadderdon S et al (2014) Epoxyeicosatrienoic acids mediate insulin-mediated augmentation in skeletal muscle perfusion and blood volume. Am J Physiol Endocrinol Metab 307:E1097–E1104CrossRefPubMedPubMedCentral
37.
go back to reference Chen W, Yang S, Ping W, Fu X, Xu Q, Wang J (2015) CYP2J2 and EETs protect against lung ischemia/reperfusion injury via anti-inflammatory effects in vivo and in vitro. Cell Physiol Biochem 35:2043–2054CrossRefPubMed Chen W, Yang S, Ping W, Fu X, Xu Q, Wang J (2015) CYP2J2 and EETs protect against lung ischemia/reperfusion injury via anti-inflammatory effects in vivo and in vitro. Cell Physiol Biochem 35:2043–2054CrossRefPubMed
38.
go back to reference Liu W, Wang B, Ding H, Wang DW, Zeng H (2014) A potential therapeutic effect of CYP2C8 overexpression on anti-TNF-α activity. Int J Mol Med 34:725–732PubMedPubMedCentral Liu W, Wang B, Ding H, Wang DW, Zeng H (2014) A potential therapeutic effect of CYP2C8 overexpression on anti-TNF-α activity. Int J Mol Med 34:725–732PubMedPubMedCentral
39.
go back to reference Laakso M, Edelman SV, Brechtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844–1852CrossRefPubMedPubMedCentral Laakso M, Edelman SV, Brechtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844–1852CrossRefPubMedPubMedCentral
41.
go back to reference Cowart LA, Wei S, Hsu MH et al (2002) The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277:35105–35112CrossRefPubMed Cowart LA, Wei S, Hsu MH et al (2002) The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277:35105–35112CrossRefPubMed
42.
go back to reference White CC, Feng Q, Cupples LA et al (2013) CYP4A11 variant is associated with high-density lipoprotein cholesterol in women. Pharm J 13:44–51 White CC, Feng Q, Cupples LA et al (2013) CYP4A11 variant is associated with high-density lipoprotein cholesterol in women. Pharm J 13:44–51
43.
go back to reference Ramirez CE, Shuey MM, Milne GL, et al. (2014) Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins Other Lipid Mediat 113–115: 38–44 Ramirez CE, Shuey MM, Milne GL, et al. (2014) Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins Other Lipid Mediat 113–115: 38–44
44.
go back to reference Wang CP, Hung WC, Yu TH et al (2010) Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes 118:346–352CrossRefPubMed Wang CP, Hung WC, Yu TH et al (2010) Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes 118:346–352CrossRefPubMed
45.
go back to reference Zeldin DC, Foley J, Boyle JE et al (1997) Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138:1338–1346CrossRefPubMed Zeldin DC, Foley J, Boyle JE et al (1997) Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138:1338–1346CrossRefPubMed
46.
go back to reference Falck JR, Manna S, Moltz J, Chacos N, Capdevila J (1983) Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 114:743–749CrossRefPubMed Falck JR, Manna S, Moltz J, Chacos N, Capdevila J (1983) Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 114:743–749CrossRefPubMed
47.
go back to reference Turk J, Wolf BA, Comens PG, Colca J, Jakschik B, McDaniel ML (1985) Arachidonic acid metabolism in isolated pancreatic islets. IV. Negative ion-mass spectrometric quantitation of monooxygenase product synthesis by liver and islets. Biochim Biophys Acta 835:1–17CrossRefPubMed Turk J, Wolf BA, Comens PG, Colca J, Jakschik B, McDaniel ML (1985) Arachidonic acid metabolism in isolated pancreatic islets. IV. Negative ion-mass spectrometric quantitation of monooxygenase product synthesis by liver and islets. Biochim Biophys Acta 835:1–17CrossRefPubMed
48.
go back to reference Flagg TP, Enkvetchakul D, Koster JC, Nichols CG (2010) Muscle KATP channels: recent insights to energy sensing and myoprotection. Physiol Rev 90:799–829CrossRefPubMedPubMedCentral Flagg TP, Enkvetchakul D, Koster JC, Nichols CG (2010) Muscle KATP channels: recent insights to energy sensing and myoprotection. Physiol Rev 90:799–829CrossRefPubMedPubMedCentral
49.
go back to reference Lu T, Ye D, Wang X et al (2006) Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol 575:627–644CrossRefPubMedPubMedCentral Lu T, Ye D, Wang X et al (2006) Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol 575:627–644CrossRefPubMedPubMedCentral
50.
go back to reference Yadav VR, Hong KL, Zeldin DC, Nayeem MA (2016) Vascular endothelial over-expression of soluble epoxide hydrolase (Tie2-sEH) enhances adenosine A1 receptor-dependent contraction in mouse mesenteric arteries: role of ATP-sensitive K+ channels. Mol Cell Biochem 422:197–206CrossRefPubMed Yadav VR, Hong KL, Zeldin DC, Nayeem MA (2016) Vascular endothelial over-expression of soluble epoxide hydrolase (Tie2-sEH) enhances adenosine A1 receptor-dependent contraction in mouse mesenteric arteries: role of ATP-sensitive K+ channels. Mol Cell Biochem 422:197–206CrossRefPubMed
Metadata
Title
Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans
Authors
Mahesha H. Gangadhariah
Blake W. Dieckmann
Louise Lantier
Li Kang
David H. Wasserman
Manuel Chiusa
Charles F. Caskey
Jaime Dickerson
Pengcheng Luo
Jorge L. Gamboa
Jorge H. Capdevila
John D. Imig
Chang Yu
Ambra Pozzi
James M. Luther
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 6/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4260-0

Other articles of this Issue 6/2017

Diabetologia 6/2017 Go to the issue